abacavir
Antiinfectives for systemic use (J05)US regulatory status: approved.
pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
AstraZeneca drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB HQ
79,242 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
AstraZeneca pipeline
Portfolio lens on 200 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
AstraZeneca drug portfolio — 200 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
US regulatory status: approved.
-
abemaciclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
abiraterone
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in AstraZeneca's portfolio. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Steroid 5-alpha-reductase inhibitor
-
abiraterone acetate
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Steroid 17-alpha-hydroxylase/17,20 lyase.
- Target
- Steroid 17-alpha-hydroxylase/17,20 lyase
- Mechanism
- Cytochrome P450 17A1 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
acalabrutinib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
US regulatory status: approved. Molecular target: Tyrosine-protein kinase BTK.
- Target
- Tyrosine-protein kinase BTK
- Mechanism
- Tyrosine-protein kinase BTK inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Plasminogen.
- Target
- Plasminogen
- Mechanism
- Tissue-type plasminogen activator inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
andexanet alfa
Various (V03)Various (V03) compound in AstraZeneca's portfolio. Molecular target: Apixaban.
- Target
- Apixaban
- Mechanism
- Tissue factor pathway inhibitor inhibitor
-
anifrolumab
Antineoplastic and immunomodulating agents (L04)Antineoplastic and immunomodulating agents (L04) compound in AstraZeneca's portfolio. Molecular target: Interferon alpha/beta receptor 1.
- Target
- Interferon alpha/beta receptor 1
- Mechanism
- Interferon-alpha/beta receptor alpha chain antagonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
apalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
apixaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
asenapine
Nervous system (N05)US regulatory status: approved. Mechanism: Serotonin 2a (5-HT2a) receptor antagonist.
- Mechanism
- Serotonin 2a (5-HT2a) receptor antagonist
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
US regulatory status: approved.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
benralizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5 receptor subunit alpha.
- Target
- Interleukin-5 receptor subunit alpha
- Mechanism
- Interleukin-5 receptor subunit alpha inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Unknown.
- Mechanism
- Unknown
-
bevacizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor A, long form.
- Target
- Vascular endothelial growth factor A, long form
- Mechanism
- Vascular endothelial growth factor A inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Beta-1 adrenergic receptor antagonist.
- Mechanism
- Beta-1 adrenergic receptor antagonist
-
bortezomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
budesonide
Alimentary tract and metabolism (A07)US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
-
US regulatory status: approved.
-
US regulatory status: approved.
-
US regulatory status: approved. Mechanism: Dihydrofolate reductase inhibitor.
- Mechanism
- Dihydrofolate reductase inhibitor
-
US regulatory status: approved. Mechanism: Mineral supplement.
- Mechanism
- Mineral supplement
-
camizestrant
Antineoplastic and immunomodulating agents (L02)Antineoplastic and immunomodulating agents (L02) compound in AstraZeneca's portfolio. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha degrader
-
capecitabine
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
capivasertib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Serine/threonine-protein kinase AKT.
- Target
- Serine/threonine-protein kinase AKT
- Mechanism
- Serine/threonine-protein kinase AKT inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium channel alpha subunit.
- Target
- Sodium channel alpha subunit
- Mechanism
- Sodium channel alpha subunit blocker
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
carfilzomib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: 26S proteasome.
- Target
- 26S proteasome
- Mechanism
- 26S proteosome inhibitor
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Adrenergic receptor alpha-1.
- Target
- Adrenergic receptor alpha-1
- Mechanism
- Adrenergic receptor beta antagonist
-
US regulatory status: approved. Molecular target: 3-hydroxy-3-methylglutaryl-coenzyme A reductase.
- Target
- 3-hydroxy-3-methylglutaryl-coenzyme A reductase
- Mechanism
- HMG-CoA reductase inhibitor
-
cetuximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
covid-19 vaccine (inactivated, adjuvanted, adsorbed)
Antiinfectives for systemic use (J07)Antiinfectives for systemic use (J07) compound in AstraZeneca's portfolio. Mechanism: Biological vaccine - induces immune response.
- Mechanism
- Biological vaccine - induces immune response
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
dapagliflozin
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Sodium/glucose cotransporter 2.
- Target
- Sodium/glucose cotransporter 2
- Mechanism
- Sodium/glucose cotransporter 2 inhibitor
-
daratumumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1.
- Target
- ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1
- Mechanism
- Lymphocyte differentiation antigen CD38 inhibitor
-
darolutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
datopotamab deruxtecan
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- Tumor-associated calcium signal transducer 2 binding agent
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved.
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Histamine H1 receptor antagonist.
- Mechanism
- Histamine H1 receptor antagonist
-
US regulatory status: approved. Molecular target: Histamine H1 receptor.
- Target
- Histamine H1 receptor
- Mechanism
- Histamine H1 receptor antagonist
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
doxorubicin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Mechanism: DNA topoisomerase II alpha inhibitor.
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
doxorubicin hydrochloride
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
-
durvalumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
edoxaban
Blood and blood forming organs (B01)US regulatory status: approved. Mechanism: Coagulation factor X inhibitor.
- Mechanism
- Coagulation factor X inhibitor
-
US regulatory status: approved. Molecular target: T cell surface glycoprotein CD3.
- Target
- T cell surface glycoprotein CD3
- Mechanism
- T cell surface glycoprotein CD3 binding agent
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
enfortumab vedotin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: Nectin-4.
- Target
- Nectin-4
- Mechanism
- Tubulin inhibitor
-
enzalutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
esomeprazole
Alimentary tract and metabolism (A02)Alimentary tract and metabolism (A02) compound in AstraZeneca's portfolio. Mechanism: Potassium-transporting ATPase inhibitor.
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
formoterol
Respiratory system (R03)Respiratory system (R03) compound in AstraZeneca's portfolio. Mechanism: Beta-2 adrenergic receptor agonist.
- Mechanism
- Beta-2 adrenergic receptor agonist
-
formoterol (fumarate)
Respiratory system (R03)Respiratory system (R03) compound in AstraZeneca's portfolio. Molecular target: Beta-2 adrenergic receptor.
- Target
- Beta-2 adrenergic receptor
- Mechanism
- Beta-2 adrenergic receptor agonist
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: DNA polymerase (alpha/delta/epsilon).
- Target
- DNA polymerase (alpha/delta/epsilon)
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
US regulatory status: approved. Molecular target: Glucagon receptor.
- Target
- Glucagon receptor
- Mechanism
- Glucagon receptor agonist
-
glycopyrronium
Respiratory system (R03)Respiratory system (R03) compound in AstraZeneca's portfolio. Mechanism: Muscarinic acetylcholine receptor inhibitor.
- Mechanism
- Muscarinic acetylcholine receptor inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
US regulatory status: approved. Molecular target: Gonadotropin-releasing hormone receptor.
- Target
- Gonadotropin-releasing hormone receptor
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Muscarinic acetylcholine receptor M1.
- Target
- Muscarinic acetylcholine receptor M1
- Mechanism
- Muscarinic acetylcholine receptor M1 antagonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
human heterologous liver cells
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in AstraZeneca's portfolio.
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Mu opioid receptor agonist.
- Mechanism
- Mu opioid receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
infliximab
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
US regulatory status: approved. Molecular target: Tumor necrosis factor.
- Target
- Tumor necrosis factor
- Mechanism
- TNF-alpha inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
ipilimumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
irinotecan hydrochloride trihydrate
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: DNA topoisomerase 1.
- Target
- DNA topoisomerase 1
- Mechanism
- DNA topoisomerase I inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
lenvatinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor.
- Target
- Vascular endothelial growth factor receptor
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
mepolizumab
Respiratory system (R03)US regulatory status: approved. Molecular target: Interleukin-5.
- Target
- Interleukin-5
- Mechanism
- Interleukin-5 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: Mitochondrial complex I (NADH dehydrogenase) inhibitor.
- Mechanism
- Mitochondrial complex I (NADH dehydrogenase) inhibitor
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
midazolam
Nervous system (N05)US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.
- Target
- GABA-A receptor; anion channel
- Mechanism
- GABA-A receptor; anion channel positive allosteric modulator
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Folate receptor alpha.
- Target
- Folate receptor alpha
- Mechanism
- Folate receptor alpha binding agent
-
mirvetuximab soravtansine
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: Folate receptor alpha.
- Target
- Folate receptor alpha
- Mechanism
- Tubulin inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
mycophenolate mofetil
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Inosine-5'-monophosphate dehydrogenase (IMPDH).
- Target
- Inosine-5'-monophosphate dehydrogenase (IMPDH)
- Mechanism
- Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
nivolumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
obinutuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
olaparib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: PARP 1, 2 and 3.
- Target
- PARP 1, 2 and 3
- Mechanism
- PARP 1, 2 and 3 inhibitor
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: Potassium-transporting ATPase.
- Target
- Potassium-transporting ATPase
- Mechanism
- Potassium-transporting ATPase inhibitor
-
US regulatory status: approved. Molecular target: 5-hydroxytryptamine receptor 3A.
- Target
- 5-hydroxytryptamine receptor 3A
- Mechanism
- Serotonin 3a (5-HT3a) receptor antagonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
orlistat
Alimentary tract and metabolism (A08)US regulatory status: approved. Molecular target: Gastric triacylglycerol lipase.
- Target
- Gastric triacylglycerol lipase
- Mechanism
- Pancreatic lipase inhibitor
-
osimertinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in AstraZeneca's portfolio. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
palbociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: CDK6/cyclin D1.
- Target
- CDK6/cyclin D1
- Mechanism
- Cyclin-dependent kinase 4/cyclin D1 inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Fatty-acid amide hydrolase 1.
- Target
- Fatty-acid amide hydrolase 1
- Mechanism
- Anandamide amidohydrolase inhibitor
-
pegfilgrastim
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Granulocyte colony-stimulating factor receptor.
- Target
- Granulocyte colony-stimulating factor receptor
- Mechanism
- Granulocyte colony stimulating factor receptor agonist
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
pemetrexed
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
pertuzumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Receptor tyrosine-protein kinase erbB-2.
- Target
- Receptor tyrosine-protein kinase erbB-2
- Mechanism
- Receptor protein-tyrosine kinase erbB-2 inhibitor
-
pioglitazone
Alimentary tract and metabolism (A10)Alimentary tract and metabolism (A10) compound in AstraZeneca's portfolio. Mechanism: Peroxisome proliferator-activated receptor gamma agonist.
- Mechanism
- Peroxisome proliferator-activated receptor gamma agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Osmotic laxative.
- Mechanism
- Osmotic laxative
-
pomalidomide
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: CRL4(CRBN) E3 ubiquitin ligase.
- Target
- CRL4(CRBN) E3 ubiquitin ligase
- Mechanism
- CRL4(CRBN) E3 ubiquitin ligase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Glucocorticoid receptor.
- Target
- Glucocorticoid receptor
- Mechanism
- Glucocorticoid receptor agonist
-
US regulatory status: approved. Molecular target: Progesterone receptor.
- Target
- Progesterone receptor
- Mechanism
- Progesterone receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
ramucirumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Vascular endothelial growth factor receptor 2.
- Target
- Vascular endothelial growth factor receptor 2
- Mechanism
- Vascular endothelial growth factor receptor 2 inhibitor
-
ranolazine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Sodium channel protein type 4 subunit alpha.
- Target
- Sodium channel protein type 4 subunit alpha
- Mechanism
- Sodium channel protein type IV alpha subunit blocker
-
ribociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
rituximab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
US regulatory status: approved. Molecular target: B-lymphocyte antigen CD20.
- Target
- B-lymphocyte antigen CD20
- Mechanism
- B-lymphocyte antigen CD20 binding agent
-
rivaroxaban
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Coagulation factor X.
- Target
- Coagulation factor X
- Mechanism
- Coagulation factor X inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Mechanism: HMG-CoA reductase inhibitor.
- Mechanism
- HMG-CoA reductase inhibitor
-
Development asset linked to AstraZeneca in public FDA and regional records. Molecular target: Tissue-type plasminogen activator.
- Target
- Tissue-type plasminogen activator
- Mechanism
- Tissue-type plasminogen activator exogenous protein
-
Development asset linked to AstraZeneca in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor.
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
-
US regulatory status: approved. Molecular target: Dual specificity mitogen-activated protein kinase kinase 1.
- Target
- Dual specificity mitogen-activated protein kinase kinase 1
- Mechanism
- Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
-
semaglutide
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Glucagon-like peptide 1 receptor.
- Target
- Glucagon-like peptide 1 receptor
- Mechanism
- Glucagon-like peptide 1 receptor agonist
-
Development asset linked to AstraZeneca in public FDA and regional records.